This　study　aims　to　evaluate　the　expression　of　the　anti-oncogene　phosphatase　and　tensin　(PTEN)　homologue　and　survivin,　a　protein　encoded　by　the　anti-apoptotic　gene　baculoviral　inhibitor　of　apoptosis　repeat　containing　5　(BIRC5),　in　the　progression　of　cervical　neoplasia　and　to　elucidate　the　relationship　between　PTEN　and　survivin　expression　based　on　clinicopathological　features　in　squamous　cell　carcinoma　of　the　uterine　cervix.　A　total　of　20　patients　with　cervical　ectropion　and　squamous　metaplasia,　30　with　cervical　intraepithelial　neoplasia,　and　49　with　cervical　squamous　cell　carcinoma　were　enrolled　in　the　study.　Immunohistochemical　staining　was　performed　to　detect　PTEN　and　survivin　expression　in　each　group.　Normal　cervical　epithelium　from　10　people　served　as　the　control.　Results　showed　that　PTEN　expression　progressively　decreased　with　the　continuum　from　normal　epithelium　to　squamous　cell　carcinoma　(P＜0.05),　whereas　survivin　expression　progressively　increased　(P＜0.05).　Furthermore,　positive　PTEN　immunostaining　was　associated　with　clinical　stage　and　tumour　size　(P＜0.05).　The　level　of　PTEN　expression　in　the　metastatic　pelvic　lymph　node　group　was　significantly　lower　compared　with　the　non-metastatic　pelvic　lymph　node　group　(P＜0.01).　Positive　PTEN　immunostaining　was　not　associated　with　age　or　degree　of　differentiation　(P＞0.05).　Positive　survivin　immunostaining　was　associated　with　clinical　stage　and　tumour　size　(P＜0.05).　Survivin-positive　expression　in　the　metastatic　pelvic　lymph　node　group　was　significantly　higher　compared　with　the　non-metastatic　pelvic　lymph　node　group　(P＜0.01).　No　obvious　relationship　was　found　between　survivin　expression　and　patient　age　(P＞0.05).　PTEN　expression　negatively　correlated　with　survivin　expression　in　cervical　intraepithelial　neoplasia　and　cervical　squamous　cell　carcinoma　(P＜0.01).　PTEN　and　survivin　expression　correlated　with　incidence　and　progression　of　uterine　cervical　cancer.　Positive　expression　levels　of　PTEN　and　survivin　provide　potential　evaluation　indices　for　early　diagnosis　and　prognosis　of　uterine　cervical　cancer,　and　these　biomarkers　are　also　potentially　promising　therapeutic　targets.